Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alnylam Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 Next >
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast TTR Investor Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Issues 2023 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.